Procept Biorobotics (PRCT) Q4 2025: Handpiece Price Up 5% as Bulk Discount Era Ends
Procept Biorobotics’ Q4 marks a pivotal shift in commercial discipline, ending bulk handpiece discounts and realigning its sales force to drive sustainable procedure-led growth. The transition temporarily pressures revenue and margins, but management signals this is foundational for long-term profitability and margin expansion. Investors should watch for execution on procedure growth and stabilization of the new operating model as the year progresses.
Summary
- Pricing Reset Drives Margin Focus: Elimination of bulk handpiece discounts realigns revenue with actual procedure demand.
- Sales Force Overhaul Introduces Short-Term Disruption: Commercial reorganization creates near-term headwinds but aims for more repeatable growth.
- Guidance Signals Back-Half Acceleration: Leadership expects procedure growth to rebound as new initiatives mature throughout 2026.
Performance Analysis
Procept Biorobotics’ Q4 2025 results reflect a deliberate break from legacy practices, prioritizing sustainable revenue quality over short-term sales volume. The company’s decision to end bulk handpiece discounts and align shipments with procedure volumes led to a pronounced reduction in handpiece sales, with unit sales dropping to approximately 80% of procedures—historically, units exceeded procedures by 8% to 16%. This reset, while compressing near-term revenue, drove a sequential 5% increase in average selling price (ASP) for handpieces to $3,340 and is expected to underpin a further ASP increase to $3,500 in 2026.
System placements remained stable, with 65 new Hydro systems sold and the installed base rising 42% year-over-year to 718. U.S. procedure volumes grew 69% YoY, underscoring robust underlying demand for Aquablation, Procept’s robotic BPH therapy platform. However, gross margin contracted to 60.6%, impacted by lower consumable revenue and a one-time field action. Operating expenses rose 22% YoY as the company invested in commercial expansion, R&D, and clinical trials, leading to a widened net loss and adjusted EBITDA loss.
- Handpiece Revenue Mix Shift: Revenue now tracks procedure volume more closely, reducing inventory-driven lumpiness and improving predictability.
- Gross Margin Compression: Margin shortfall was driven by lower consumable sales and a voluntary field action, but full-year margins improved YoY.
- Operating Expense Growth: Increased spending supports commercial and clinical expansion, but EBITDA loss widened as a result.
Leadership’s guidance for 2026 bakes in these structural changes, projecting 27% to 33% revenue growth, with procedure growth expected to accelerate in the second half as the new sales model matures.
Executive Commentary
"I've always believed pricing discipline is foundational to long-term success at Procept. I've been focused on implementation of handpiece price discipline and as part of that we eliminated the historical practice of providing discounts on bulk purchases particularly at the end of the quarter. Despite customer requests we remain disciplined and do not allow bulk purchases at a discount as a result handpiece unit sales were approximately 80% of procedures in the fourth quarter. And for the first time, procedures exceeded handpiece to sole. While this resulted in lower than expected revenue, it delivered a significant improvement in handpiece selling price."
Larry Wood, Chief Executive Officer
"Our revised revenue guidance reflects positive EBITDA in the fourth quarter of 2026 at both the low and high ends of the revenue range. For the first quarter, we expect total U.S. procedures to be in the range of 12,000 to 12,800, representing growth of 29 to 37%. This anticipates the implementation of multiple commercial initiatives designed to drive more durable and sustainable procedure growth. As these initiatives take hold, we expect procedures to accelerate, reaching growth of over 50% in the second half of the year compared to fiscal 2025."
Kevin Waters, Chief Financial Officer
Strategic Positioning
1. Handpiece Pricing and Inventory Discipline
By ending bulk discounting and aligning handpiece shipments to actual procedure volumes, Procept is prioritizing sustainable, margin-accretive growth over volume-driven sales cycles. This shift is expected to reduce revenue volatility and improve ASP, supporting a clearer path to profitability.
2. Commercial Organization Realignment
The company restructured its sales and clinical teams into integrated regional units, with a dedicated launch team focused on new system placements. This model aims to accelerate time-to-value for new customers and drive more consistent procedure growth, though it introduces temporary field disruption as tenured staff transition roles.
3. Procedure Growth as the Core Health Metric
Leadership is steering investors to focus on procedure growth, not just handpiece sales, as the true indicator of business vitality. Q4’s 69% YoY procedure growth demonstrates robust patient demand, and the company expects to maintain procedure-led expansion as the main lever for share gains in the underpenetrated BPH market.
4. Margin and Profitability Roadmap
Despite Q4 margin pressure, Procept is guiding for full-year 2026 gross margin improvement (65%), aided by higher ASP and operational leverage, though tariffs will remain a headwind. The company targets positive EBITDA by Q4 2026, with operating expense growth moderating as commercial investments yield returns.
5. Market Development and Patient Activation
Procept acknowledges previous underinvestment in patient and clinician education, with new targeted initiatives planned for 2026. The company sees substantial headroom in both share capture among treated BPH patients and broader patient activation, but will pursue cost-effective, targeted campaigns rather than broad media spend.
Key Considerations
This quarter marks a structural inflection point for Procept, with management choosing to absorb short-term pain for long-term gain. The success of this strategy will depend on execution, the durability of procedure growth, and the ability to stabilize the new commercial model.
Key Considerations:
- Handpiece ASP Expansion: Pricing discipline is expected to drive a 9% YoY increase in handpiece ASP, offsetting lower unit sales.
- Sales Force Transition Risk: Short-term disruption is anticipated as tenured staff shift roles and rebuild customer relationships; stabilization is expected by mid-year.
- Gross Margin Leverage: Margin recovery depends on sustained ASP gains and normalization of consumable revenue, with tariffs a continued drag.
- System Placement Stability: 2026 system placements are modeled flat to up, with ASP expected to remain steady or improve, supporting installed base growth.
- Market Penetration Opportunity: With only 10% penetration among surgical BPH patients, significant runway remains for share gains and patient activation.
Risks
Execution risk is elevated as Procept implements major commercial changes and ends long-standing discount practices. There is potential for further near-term disruption if customers or field teams struggle to adapt, or if procedure growth falls short of expectations. Tariff expense and operating cost inflation will weigh on margins, while competitive therapies and payer dynamics could pressure procedure volume. Investors should monitor for any signs of recurring inventory or demand volatility, as well as progress on patient activation and clinical adoption initiatives.
Forward Outlook
For Q1 2026, Procept guided to:
- U.S. procedure volumes of 12,000 to 12,800, up 29% to 37% YoY
- Total revenue of $79 to $82 million, up 14% to 19% YoY
For full-year 2026, management lowered guidance to:
- Total revenue of $390 to $410 million, representing 27% to 33% YoY growth
- Gross margin of approximately 65%, with $5-6 million in tariff expense
- Positive EBITDA in Q4 2026 at both ends of the revenue range
Management highlighted several factors that shape the outlook:
- Procedure growth expected to accelerate in the back half as commercial initiatives mature
- Handpiece ASP uplift is expected to offset lower unit volume
- Operating expense growth to moderate as investments in sales and clinical teams stabilize
Takeaways
Procept is executing a high-conviction reset, trading near-term revenue softness for higher quality, more predictable growth and margin expansion.
- Commercial Discipline Over Volume: Ending bulk handpiece discounts aligns revenue with true demand and supports sustainable ASP and margin improvement.
- Operational Disruption Is a Calculated Bet: Sales force realignment and launch team formation introduce transition risk, but are designed to create repeatable, scalable growth engines.
- Watch for Procedure Growth and Margin Rebound: Back-half acceleration in procedure volumes and stabilization of gross margin will be critical signals of execution and market health.
Conclusion
Procept Biorobotics’ Q4 2025 is defined by a decisive pivot toward sustainable, margin-driven growth, even at the cost of near-term turbulence. The company’s willingness to reset commercial practices and invest in scalable infrastructure positions it for long-term expansion, but success now hinges on execution and the realization of procedure-led growth throughout 2026.
Industry Read-Through
Procept’s abrupt end to bulk discounting and inventory-driven sales cycles is a signal to the broader MedTech sector: sustainable growth increasingly requires discipline in pricing, inventory, and commercial deployment, not just top-line expansion. The focus on aligning revenue with underlying procedure demand and investing in high-impact commercial infrastructure is likely to be echoed by other device companies facing similar volatility and margin pressures. Investors should watch for similar resets across the surgical robotics and consumable-driven device landscape, especially as the market rewards predictability, margin leverage, and scalable execution over near-term volume at any price.